ClinicalTrials.gg
Status unknownNCT04667598Updated Dec 14, 2020

Clinical and Metabonomics Study on the Treatment of Heart Failure After Myocardial Infarction With Modified Wenxin Decoction

A Phase 2 interventional study of Modified Wenxin Decoction in Heart Failure and Myocardial Infarction, sponsored by Jun Li. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-14.

Sponsored by Jun Li · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To elucidate the efficacy and safety of weixin decoction in the treatment of heart failure after myocardial infarction.

Read the detailed description

To elucidate the long-term protective effect of flavored Wenxin Decoction on heart failure after myocardial infarction.

To elucidate the effective components in the treatment of heart failure and the mechanism of metabolism regulation.

02

Conditions studied

  • Heart Failure
  • Myocardial Infarction

Keywords

  • Traditional Chinese Medicine
03

In context

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

This study's planned enrollment of 200 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Jun Li is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-75 years old;
  • A history of acute myocardial infarction;
  • Cardiac function Ⅱ - Ⅲ level;
  • 50% or less;
  • Nt-probnp level ≥ 450 pg/ mL;
  • All men and women can sign the form.

Exclusion criteria

Exclusion Criteria:

  • Coronary artery bypass grafting was performed within 12 weeks;
  • Undergo or possibly undergo cardiac resynchronization therapy;
  • Primary valvular disease, left ventricular outflow tract obstruction, myocarditis, aneurysm, uncontrolled severe arrhythmia, cardiogenic shock, unstable angina pectoris, or acute myocardial infarction;
  • Having a serious primary liver, kidney or blood system disease or having a serious mental illness or a systemic disease that is out of control;
  • Serum creatinine > 194.5 mol/L or serum potassium > 5.5mmol /L;
  • The level of or alkaline phosphatase is 1.5 times of the normal upper limit of >;
  • Abnormal blood pressure control, systolic blood pressure exceeding 180mmHg or diastolic blood pressure exceeding 110mmHg;
  • Pregnancy or lactation; Known or suspected allergy to research drugs; To receive another drug within 30 days of randomization or to be unwilling or unable to provide written consent.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Experimental group

    On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given modified Wenxin Tang granules, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.

    Drug: Modified Wenxin Decoction

  • Placebo comparator
    Control group

    On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.

    Drug: Modified Wenxin Decoction

Interventions

  • DrugModified Wenxin Decoction

    Mainly including make aconite , astragalus , Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Major cardiovascular events

    Rates of cardiac death, acute myocardial infarction, stroke, and heart failure readmission

    Time frame: One months after drug intervention

Secondary outcomes

  1. Secondary indicators

    NT-proBNP, six-minute walking experiment and echocardiographic

    Time frame: Into the group day 1, week 4, week 8, week 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31. No abstract available. Erratum In: Circulation. 2018 Mar 20;137(12):e493. doi: 10.1161/CIR.0000000000000573. PubMed 29386200 ↗
  • Hildebrandt P. Systolic and nonsystolic heart failure: equally serious threats. JAMA. 2006 Nov 8;296(18):2259-60. doi: 10.1001/jama.296.18.2259. No abstract available. PubMed 17090774 ↗
  • Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998 Jan 27;97(3):282-9. doi: 10.1161/01.cir.97.3.282. No abstract available. PubMed 9462531 ↗
  • Gerber Y, Melton LJ 3rd, Weston SA, Roger VL. Association between myocardial infarction and fractures: an emerging phenomenon. Circulation. 2011 Jul 19;124(3):297-303. doi: 10.1161/CIRCULATIONAHA.110.007195. Epub 2011 Jun 27. PubMed 21709062 ↗
  • Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol. 2009 Jan 6;53(1):13-20. doi: 10.1016/j.jacc.2008.08.067. PubMed 19118718 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2020; primary completion for Jun 2022, 18 months later.

Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 18 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2020
First posted
Dec 14, 2020
StartEst.
Dec 15, 2020
Primary completionEst.
Jun 30, 2022
CompletionEst.
Jun 30, 2023
Last update
Dec 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04667598
Lead sponsor
Jun Li
Responsible party
Jun Li (Li Jun, Guang'anmen Hospital of China Academy of Chinese Medical Sciences) — Sponsor-investigator
First posted
Dec 14, 2020
Start date
Dec 15, 2020 (estimated)
Primary completion
Jun 30, 2022 (estimated)
Completion
Jun 30, 2023 (estimated)
Last update
Dec 14, 2020

Study contacts

Jun Li, MD
Contact
gamyylj@163.com
13051458913
Jun Li, MD
study director · Guang 'anmen Hospital of China Academy of Chinese Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion